OmniSeq
OmniSeq Receives New York State Approval for Cancer Genomic, Immune Profiling Test
The Insight test, which detects genomic variants, signatures, and immune gene expression to inform cancer treatment, will now be available to patients in New York.
OmniSeq, UPMC Partner on Immunotherapy Trial Matching for Head and Neck Cancer
The Phase II trial will use OmniSeq's RNA-seq assay to determine whether patients should be treated with one of two agents combined with BMS' nivolumab.